Johnson & Johnson Vision Care, Inc.
Clinical Study Protocol
Clinical Evaluation of etafilcon A with Ketotifen
Protocol CR-5930Version: v3.0, Amendment 2.0Date: 31 October 2017Investigational Products: etafilcon A with 0.019 mg ketotifen ( K-Lens)
Key Words: etafilcon A, etafilcon A with ketotifen, 1-DAY ACUVU E
®Brand Contact Lenses, 
Daily Disposable, Dispensing, logMAR visual acuity, K-Lens, Pla cebo, Wearing Time, 
CLUE™ Handling, daily wear.Statement of Compliance to protocol, GCP and applicable regulat ory guidelines:
This trial will be conducted in compliance with the protocol, I SO 14155,
1the International 
Conference on Harmonization Good Clinical Practice E6 (ICH-GCP) ,2the Declaration of 
Helsinki,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confidential information, which should n ot be copied, referred to, 
released or published without written approval from Johnson & Johnson Vision Care, Inc.  The information may not be disclosed to others except to the extent  necessary to obtain Institutional 
Review Board/Independent Ethics Committee approval and informed  consent, or as required 
by International, Federal and State Laws, as applicable. Person s to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it 
should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc.  Any supplemental information that may be added to t his document is also 
confidential and proprietary to Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-5930, v3.0 Amendment 2.0
               Page 1 of 97JJVC CONFIDENTIAL
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION................................ ........................................... 6  
SPONSOR NAME AND ADDRESS....................................... ................................................ 6  
MEDICAL MONITOR................................................ ............................................................. 6  
AUTHORIZED SIGNATURES............................................................................................... 7  
CHANGE HISTORY................................................................................................................ 8  
SYNOPSIS....................................................... ......................................................................... 9  
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS ........... ......... 14  
1. INTRODUCTION AND BACKGROUND .................................... ............................... 16  
1.1. Name and Descriptions of Investigational Products ................................................ 16  
1.2. Intended Use of Investigational Products................................................................. 17  
1.3. Summary of Findings from Nonclinical Studies................... ................................... 17  
1.4. Summary of Known Risks and Benefits to Human Subjects.......... ......................... 17  
1.5. Relevant Literature References and Prior Clinical Data Relevant  to Proposed Clinical 
Study... ................................................................................................................................ 18  
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ..................... ................. 18  
2.1. Objectives................................................................................................................. 18  
2.2. Endpoints.................................................................................................................. 18  
2.3. Hypotheses ............................................................................................................... 19  
3. TARGETED STUDY POPULATION........................................................................... 19  
3.1. General Characteristics ........................................ .................................................... 19  
3.2. Inclusion Criteria............................................. ......................................................... 19  
3.3. Exclusion Criteria..................................................................................................... 20  
3.4. Enrollment Strategy............................................ ...................................................... 21  
4. STUDY DESIGN AND RATIONALE..................................... ..................................... 21  
4.1. Description of Study Design .................................... ................................................ 21  
4.2. Study Design Rationale............................................................................................ 21  
4.3. Enrollment Target and Study Duration ........................... ......................................... 22  
5. TEST ARTICLE ALLOCATION AND MASKING............................ ......................... 22  
5.1. Test Article Allocation........................................ ..................................................... 22  
5.2. Masking.................................................................................................................... 22  
5.3. Procedures for Maintaining and Breaking Randomization Codes.... ....................... 23  
6. STUDY INTERVENTION............................................. ................................................ 23  
6.1. Identity of Test Articles...................................... ...................................................... 23  
6.2. Ancillary Supplies/Products..................................................................................... 24  
CR-5930, v3.0 Amendment 2.0
               Page 2 of 97JJVC CONFIDENTIAL
6.3. Administration of Test Articles................................................................................ 24  
6.4. Packaging and Labeling ......................................... .................................................. 24  
6.5. Collection and Storage of Samples .............................. ............................................ 24  
6.6. Accountability of Test Articles ................................ ................................................ 24  
7. STUDY EVALUATIONS.............................................................................................. 25  
7.1. Time and Event Schedule......................................................................................... 25  
7.2. Detailed Study Procedures ....................................................................................... 26  
VISIT 1 ........................................................................................................................... 26  
VISIT 2 ........................................................................................................................... 31  
FINAL EVALUATION............................................... ................................................... 32  
7.3. Unscheduled Visits................................................................................................... 32  
7.4. Laboratory Procedures ............................................................................................. 34  
8. SUBJECTS COMPLETION/WITHDRAWAL................................. ............................. 34  
8.1. Completion Criteria.................................................................................................. 34  
8.2. Withdrawal/Discontinuation from the Study ...................... ..................................... 34  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION .............. ... 35  
10. DEVIATIONS FROM THE PROTOCOL ................................... ............................... 35  
11. STUDY TERMINATION ........................................................................................... 35  
12. PROCEDURE FOR HANDLING PR ODUCT QUALITY COMPLAINTS.............. 36 
13. ADVERSE EVENTS................................................................................................... 37  
13.1.  Definitions and Classifications............................................................................. 37  
13.2.  Assessing Adverse Events....................................... ............................................. 39  
13.2.1  Causality Assessment........................................... ............................................. 39  
13.2.2  Severity Assessment ............................................ ............................................. 40  
13.3.  Documentation and Follow-Up of Adverse Events.................. ............................ 40  
13.4.  Reporting Adverse Events....................................... ............................................. 41  
13.4.1  Reporting Adverse Events to Sponsor ............................ .................................. 42  
13.4.2  Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities
………………………………………………………………………………… 42 
13.4.3  Event of Special Interest ...................................... ............................................. 43  
13.5.  Reporting of Pregnancy......................................... ............................................... 43  
14. STATISTICAL METHODS........................................................................................ 43  
14.1.  General Considerations......................................... ................................................ 43  
14.2.  Sample Size Justification...................................................................................... 43  
14.3.  Analysis Populations ........................................... ................................................. 45  
CR-5930, v3.0 Amendment 2.0
               Page 3 of 97JJVC CONFIDENTIAL
14.4.  Level of Statistical Significance........................................................................... 45  
14.5.  Primary Analysis ............................................... ................................................... 45  
14.6.  Secondary Analysis ............................................. ................................................. 46  
14.7.  Other Exploratory Analyses ................................................................................. 46  
14.8.  Interim Analysis ................................................................................................... 46  
14.9.  Procedure for Handling Missing Data and Drop-Outs ......................................... 46  
14.10.  Procedure for Reporting Deviations from Statistical Plan ....... ............................ 46  
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING..................... ........... 47  
15.1.  Electronic Case Report Form/Data Collection .................... ................................. 47  
15.2.  Subject Record...................................................................................................... 47  
16. DATA MANAGEMENT............................................................................................. 48  
16.1.  Access to Source Data/Document ................................. ....................................... 48  
16.2.  Confidentiality of Information................................. ............................................. 48  
16.3.  Data Quality Assurance......................................... ............................................... 48  
17. MONITORING..................................................... ....................................................... 48  
18. ETHICAL AND REGULATORY ASPECTS................................. ............................ 49  
18.1.  Study-Specific Design Considerations ........................... ...................................... 49  
18.2.  Investigator Responsibility.................................... ............................................... 49  
18.3.  Independent Ethics Committee or Institutional Review Board (IEC/IRB) .......... 49  
18.4.  Informed Consent ............................................... .................................................. 51  
18.5.  Privacy of Personal Data ...................................................................................... 52  
19. STUDY RECORD RETENTION......................................... ....................................... 53  
20. FINANCIAL CONSIDERATIONS ....................................... ..................................... 53  
21. PUBLICATION........................................................................................................... 54  
22. REFERENCES ..................................................... ....................................................... 55  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)... .. 57  
APPENDIX B: PATIENT INSTRUCTION GUIDE ............................................................. 61  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)......................................... 62  
APPENDIX D: CLINICAL TECHNICAL PROCEDURES ................................ ......65 
 LENS FITTING CHARACTERISTICS ................................ .............................. 66 
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS ......................... 73 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
................................ ................................ ................................ ................................ ................. 75 
 BIOMICROSCOPY SCALE ................................ ................................ ............... 82 
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION .......................... 88 
CR-5930, v3.0 Amendment 2.0
               Page 4 of 97JJVC CONFIDENTIAL
 DISTANCE LOGMAR VI SUAL ACUITY MEASUREMENT PROCEDURE 93 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE ............. ............. 97  
LISTING OF TABLES 
Table 1: Target number of subjects by arm and site............. .................................................. 21  
Table 2: Test Articles......................................... ..................................................................... 23  
Table 3: Time and Events ....................................... ............................................................... .2 5 
Table 4: Sample size for different scenarios of mean  οandߪ.............................................. 45  
LISTING OF FIGURES
Figure 1: Study Flowchart ...................................... ............................................................... .1 3 
CR-5930, v3.0 Amendment 2.0
               Page 5 of 97JJVC CONFIDENTIAL
PROTOCOL TITLE, NUMBER, VERSION  
Title: Clinical Evaluation of etafilcon A with Ketotifen
Protocol Number: CR-5930Version: 3.0, Amendment 2.0
Date: 31 October 2017
SPONSOR NAME AND ADDRESS 
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway, 
Jacksonville, FL 32256
MEDICAL MONITOR 
Name: Kristy Canavan, OD, FAAO
Title: Principal Research OptometristAddress: 7500 Centurion Parkway, Jacksonville, FL 32256
Email: KCANAVA2@its.jnj.comThe Medical Monitor must be notified by the clinical institution/site by e-mail or telephone
within 24 hours of learning of a Serious Adverse Event. The Medic al Monitor may be 
contacted during business hours for adverse event questions.  General study related questions should be directed towards your assigned clinical research associate.
The Medical Monitoring Plan is maintained as a separate documen t and included in the Trial 
Master File.
 
CR-5930, v3.0 Amendment 2.0
               Page 6 of 97JJVC CONFIDENTIAL
AUTHORIZED SIGNATURES 
The signature below constitutes the approval of this protocol a nd the attachments, and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the
protocol, including all statements regarding confidentiality, a nd according to local legal and 
regulatory requirements and applicable U.S. federal regulations,4ICH guidelines,2ISO 14155,1
and the Declaration of Helsinki.3
Author
See Electronic Signature Report
Brian PallSenior Principal Research Optometrist Date
Clinical Operations Manager
See Electronic Signature Report
Date
Biostatistician See Electronic Signature Report
Date
Data Management See Electronic Signature Report
Date
Reviewer See Electronic Signature Report
Date
Approver See Electronic Signature Report
Date
 
CR-5930, v3.0 Amendment 2.0
               Page 7 of 97JJVC CONFIDENTIAL
SYNOPSIS  
Protocol Title Clinical Evaluation of etafilcon A with ketotifen
Sponsor Johnson & Johnson Vision Care, Inc., 7500 Centurion 
Parkway, Jacksonville, FL  32256
Clinical Phase Developmental phase: Phase 2
Trial Registration This study will be registered on ClinicalTrials.gov by the 
Sponsor
Test Article(s) Investigational Products:
K-Lens: etafilcon A with 0.019 mg ketotifen
Placebo : 1·Day ACUVUE®Brand Contact Lens
Wear and Replacement 
SchedulesWear Schedule: Daily Disposable
Replacement Schedule: Daily
Objectives The purpose of this study is to evaluate the clinical
performance of K-Lens produced on the new J&J Vision Care,
Inc. manufacturing line in Limerick, Ireland.
Study Endpoints The primary endpoint is monocular contact lens best-
corrected distance visual acuity on logMAR scale. This will 
be evaluated under high luminance and high contrast 
conditions at 4 meters from ETDRS charts at 1-Week
Follow-up Visit.
Thesecondary endpoints are:
xProportion of eyes with significant (G rade 3 or 4) slit 
lamp findings
xProportion of eyes with unacceptable lens fitting
Adverse events, subject reported ocular symptoms, 
subjective assessm ent of lens handling, number and reasons 
for discontinuation, number and reasons for unscheduled lens 
replacement including lens damage will be monitored and
summarized.
Study Design This is a randomized, double-masked, bilateral, controlled, 
two-arm parallel group, multi-site, 1-Week dispensing study.
Subjects are scheduled for 2 study visits:
xVisit 1: Initial screening, baseline evaluation, lens 
assignment , lens dispensing and clinical assessments
xVisit 2: Follow-up visit 6 to 9 days after the initial 
visit with clinical assessments and exit procedures.
See the flowchart at the end of the synopsis for the schematic 
of the study visits and procedures of main observations.
CR-5930, v3.0 Amendment 2.0
               Page 9 of 97JJVC CONFIDENTIAL
Sample Size This study will target to enroll approximately 132 subjects
with a target completion of 80 subjects in the K-Lens arm
and 40 in the Placebo arm.
Study Duration The study duration will be approximately 8 weeks
Anticipated Study 
PopulationThe study populations will be healthy normal habitual 
contact lens wearers that are  at least 18 years old and less 
than 40 years.
Eligibility Criteria Potential subjects must satisfy all of the following criteria to  
be enrolled in the study
1.The subject must read, understand, and sign the 
STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form 
2. Appear able and willing to adhere to the instructions 
set forth in this clinical protocol
3. Between 18 and 39 (inclusive) years of age at the time 
of baseline visit
4. The subject must be a habitual lens wearer for a least 
6 days/week and for a minimum of 8 hours per day 
over the last month.
5.The subject’s contact lens correction must be in the 
range of -1.00 D to -6.00 D (inclusive) in each eye.
6.The subject’s refractive cylinder must be 1.00 D or 
less in each eye 
7.Have a spherocylindrical best corrected visual acuity 
of20/30 or better in each eye ( Snellen Visual Acuity)
Potential subjects who meet any of the following criteria will 
be excluded from participating in the study:
1. Currently pregnant or lactating
2.Any systemic disease (e.g., Sjögren’s Syndrome), 
allergies, infectious disease (e.g., hepatitis, 
tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid 
arthritis), or other diseases, by self- report, which are 
known to interfere with contact lens wear and/or 
participation in the study
3.Use of systemic medications ( e.g., chronic steroid use) 
that are known to interfere with contact lens wear 
4.Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact 
lens wear and/or participati on in the study. This may 
include, but not be limited to entropion, ectropion, 
extrusions, chalazia, recurrent styes, glaucoma, history 
of recurrent corneal erosions, aphakia, or corneal distortion 
CR-5930, v3.0 Amendment 2.0
               Page 10 of 97JJVC CONFIDENTIAL
5.Any corneal distortion resulting from previous hard or 
rigid gas permeable contact lens wear, history of 
strabismus, or current monovision, multi- focal, or 
toric contact lens correction .
6.Any current use of rewetting drops or ocular 
medication
7.Any previous, or planned (during the course of the 
study) ocular surg ery (e.g., radial keratotomy, PRK, 
LASIK, etc.)
8.Any grade 3 or greater slit lamp findings (e.g., edema, 
corneal neovascularization, corneal staining, tarsal 
abnormalities, conjunctival injection) on the FDA 
Biomicroscopy Scale
9. Any previous history or signs of a contact lens- related 
corneal inflammatory event (e.g., past peripheral ulcer 
or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens 
wear
10.Any known hypersensitivity or allergic reaction to 
ketotifen
11. Participation in any eye drop, contact lens or lens care 
product clinical trial within 14 days prior to study 
enrollment
12. Employee or immediate family member of an 
employee of clinical site (e.g., Investigator, 
Coordinator, Technician)
Disallowed 
Medications/I nterventionsNo ocular medications (Rx or OTC) or any systemic 
medications that (e.g., chronic steroid use) are known to 
interfere with contact lens wear
Measurements and
ProceduresMonocular contact lens best-corr ected distance visual acuity
(measured via logMAR visual acuity charts)
Microbiology or Other 
Laboratory TestingNone
Study Termination The occurrence of one or more Unanticipated Adverse 
Device Effect (UADE), or any SAE where relationship to study agent cannot be ruled out, will result in st
opping 
further dispensing investigational product.  In the event of a 
UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the
Principal Investigator before any further subjects are 
enrolled.
Ancillary Supplies/ Study-
Specific MaterialsNone
CR-5930, v3.0 Amendment 2.0
               Page 11 of 97JJVC CONFIDENTIAL
Principal Investigator(s)
and StudyInstitution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is included in the study Trial Master File.  
CR-5930, v3.0 Amendment 2.0
               Page 12 of 97JJVC CONFIDENTIAL
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS 
ADE Adverse Device Effect
AE Adverse Event/Adverse Experience
BCVA Best Corrected Visual Acuity
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal Regulations
CLUE Contact Lens User Experience
CRA Clinical Research Associate
CRF Case Report Form
CRO Contract Research Organization
CT Center Thickness
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
ETDRS Early Treatment Diabetic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization
IDE Investigational Device Exemption
IEC Independent Ethics Committee
IRB Institutional Review Board
ISO International Organization for Standardization
ITT Intent-to-Treat
JJVC Johnson & Johnson Vision Care, Inc.
logMAR Logarithm of Minimal Angle of Resolution
MOP Manual of Procedures
NIH National Institutes of Health
OD Right Eye
OS Left Eye
OTC Over the Counter
OU Both Eyes
PD Protocol Deviation
PI Principal Investigator
PIG Patient Instruction Guide
PQC Product Quality Complaint
PRO Patient Reported Outcome
QA Quality Assurance
QC Quality Control
Rx Prescription
SAE Serious Adverse Event/Serious Adverse Experience
SAP Statistical Analysis Plan
CR-5930, v3.0 Amendment 2.0
               Page 14 of 97JJVC CONFIDENTIAL
SAS Statistical Analysis System
SD Standard Deviation
SOP Standard Operating Procedure
UADE Unanticipated Adverse Device Effect
USADE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
CR-5930, v3.0 Amendment 2.0
               Page 15 of 97JJVC CONFIDENTIAL
1. INTRODUCTION AND BACKGROUND 
The etafilcon A with ketotifen contact lens is being developed as  a novel drug/device 
combination product that incorporates the anti-allergy agent ketotifen with the same material 
as the 1•DAY ACUVUE®Brand disposable contact lens (etafilcon A daily disposable con tact
lens). This new product will be referred to hereafter as K-Lens . The control 1•DAY ACUVUE®
Brand disposable contact lens will be referred to hereafter as Placebo. Ocular allergy, and the
discomfort associated with its signs and symptoms, is a common cause of contact lens
intolerance and of seasonal exacerbation of eye allergy symptom s in contact lens wearers.5,6
The creation of a concomitant system of an anti-allergy agent a nd a contact lens will offer
significant advantages over existing therapies in that it allow s contact lens users to continue
wearing their lenses during the allergy season while preventing  ocular itching associated with
allergic conjunctivitis.
Ketotifen fumarate, a benzocycloheptathiophene derivative, is an  approved noncompetitive H 1
receptor antagonist that stabilizes mast cells and prevents eosi nophil accumulation, thus 
providing multiaction therapy. Ketotifen fumarate ophthalmic sol ution is an effective, safe, 
and well-tolerated therapy for the management of ocular allergy with a duration of action of 
up to 12 hours as demonstrated in the conjunctival allergen chall enge mode.7, 8
K-Lens has been evaluated for safety, tolerability, and efficac y (prevention of ocular itching)
in previous studies.9-20The results of these studies have shown it to be safe, tolerabl e and
efficacious. Two (2) pivotal Phase 3 studies have shown that K-L ens was effective in the
prevention of ocular itching associated with allergic conjuncti vitis at 15 minutes and 12 hours 
following lens insertion.16, 17The goal of this study is to evaluate the clinical performance of  
K-Lens produced on the new J&J Vision Care, Inc. manufacturing l ine in Limerick, Ireland,
in a population of normal, healthy, habitual contact lens weare rs.  
1.1. Name and Descriptions of Investigational Products  
The K-Lens is a combination product consisting of an etafilcon A soft hydrophilic contact 
lens with 0.019 mg ketotifen.  Additional information pertainin g to the device and drug 
components is listed below:
Device component –The device component is an etafilcon A soft contact lens equivalent to 
1-DAY ACUVUE® Brand Contact Lenses.  This product is currently c leared by Food & 
Drug Administration (FDA) under 510(k) K013973. The predicate device in this 510(k) was 
ACUVUE® (etafilcon A) Brand Contact Lenses, approved by FDA und er PMA N18-033.
The etafilcon A soft hydrophilic contact lenses have an extensive history on the United States (US) market and are indicated for the correction of refractive ametropia (myopia and 
hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00 D or less 
of astigmatism.  Lenses are to b e worn as a daily wear contact lens (periods of less than 
24 hours while awake) and disposed of after removal.
Drug component –The drug component, ketotifen, is the active ingredient in the currently 
marketed eye drop, ZADITOR
®(ketotifen fumarate ophthalmic solution, 0.035%) 
CR-5930, v3.0 Amendment 2.0
               Page 16 of 97JJVC CONFIDENTIAL
manufactured by Alcon Pharmaceuticals. ZADITOR®was originally approved under NDA 
21-0166 in 1999 as a prescription drug for the prevention of ocular itching associated with 
allergic conjunctivitis (selective H 1antihistamine/mast cell stab ilizer) and switched to over-
the-counter in 2006 (NDA 21-066/S011).  The drug component may use the Reference Listed 
Drug under NDA 021066 (ZADITOR®[ketotifen fumarate ophthalmic solution, 0.035%]).
1.2. Intended Use of Investigational Products 
The proposed intended use of K-Lens, a daily disposable contact le ns, is to provide vision 
correction while preventing ocular itching associated with alle rgic conjunctivitis. The 
prevention of itch has been demonstrated to last through 12 hou rs in clinical studies; however, 
the contact lens may be worn for longer than 12 hours for vision correction.
The intended users are phakic or aphakic patients who are suita ble for contact lens wear and 
experience ocular allergic itch due to allergic conjunctivitis and who do not have red eye(s) or 
more than 1.00 D of astigmatism. 
1.3. Summary of Findings from Nonclinical Studies 
K-Lens was shown to be biocompatible and tolerable on eye. Spec ifically, K-Lens extracts 
were shown to be non-cytotoxic, non-ocular irritating and non-s ensitizing. The extracts of K 
Lens in a packing solution were not mutagenic. K-Lens placed on  rabbit eyes has been shown 
to be non-irritating and non-toxic to the eye, and without syst emic toxicity following a 
minimum seven hours of daily lens wear for up to 6 months.21
All previous pre-clinical findings were deemed satisfactory prior to proceeding with clinical 
trials on humans.
For the most comprehensive nonclinical information regarding K-Le ns, refer to the latest 
version of the Investigator’s Brochure .21
1.4. Summary of Known Risks and Benefits to Human Subjects 
K-Lens has been evaluated for safety, tolerability, and efficacy  (prevention of ocular itching) 
in previous studies.9-20
The results from the Phase 3 safety trials for K-Lens have shown  that the risks to wearing 
K-Lens are not substantially increased as compared to other non-me dicated contact lenses 
worn in a daily disposable modality or the use of ketotifen fum arate ophthalmic drops. The 
ocular adverse events with the highest reported incidence from the Phase 3 safety trials were
instillation site irritation (3.7% ), dry eye (0.9%), eye irrita tion (0.8%). All non-ocular adverse 
events from the two Phase 3 safety trials were assessed by the Investigators as not related to 
study medication.
The benefits of K-Lens include the correction of refractive err or and the prevention of itch 
associated with allergic conjunctivitis.
CR-5930, v3.0 Amendment 2.0
               Page 17 of 97JJVC CONFIDENTIAL
For the most comprehensive clinical information regarding K-Lens r efer to the latest version 
of the Investigator’s Brochure.21
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed 
Clinical Study 
K-Lens is an investigational drug/device combination product and the clinical results have yet 
to be published. Additionally, there are no known publications r eporting clinical data with a 
contact lens containing an anti-allergy medication.
K-Lens has been evaluated in previous studies.9-20for safety, tolerability, and efficacy 
(prevention of ocular itching). A dditionally, in the previous K-L ens studies, visual acuity was 
assessed using Snellen visual acuity charts which are commonly u sed in clinical practice. The 
proposed clinical study will assess visual acuity using logMAR (ETDRS) charts which are
more commonly used in clinical research studies. By collecting data from both types of visual acuity charts, a more comprehensiv e assessment of visual acuity with K-Lens will be obtained.
For additional clinical information regarding K-Lens, refer to the  latest version of the
Investigator’s Brochure .
21
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES 
2.1. Objectives  
The purpose of this study is to evaluate the clinical performance of K-Lens produced on the 
new J&J Vision Care, Inc. manufacturing line in Limerick, Ireland.  
2.2. Endpoints  
Primary Endpoint
The primary endpoint is monocular contact lens-corrected distan ce visual acuity using a
logMAR visual acuity scale. This will be evaluated under high lumi nance and high contrast 
conditions at 4 meters from ETDRS charts at the 1-week follow-up v isit.
Secondary Endpoint(s) 
xProportion of eyes with clinically significant (Grade 3 or 4) sli t lamp findings.
xProportion of eyes with unacceptable lens fitting.
Other Endpoints  
Average daily wear time (in Hours):
Average daily wear time will be calculated as the number of hou rs between subjects reported 
time of insertion and time of removal of the study lenses, on a n average day, at 1-Week Follow-
up evaluation.
CR-5930, v3.0 Amendment 2.0
               Page 18 of 97JJVC CONFIDENTIAL
Subjective assessment of lens handling:
Lens handling will be assessed using Contact Lens User Experien ceTM(CLUE) questionnaire 
at 1-Week Follow- up evaluation. CLUE™ is a validate d patient reported outcomes (PRO) 
questionnaire to assess patient-experience attributes of soft c ontact lenses (comfort, vision, 
handling, and packaging) in a c ontact-lens wearing population i n the US, ages 18-65. Derived 
CLUE™ scores using Item Response Theory (IRT) follow a normal distribution with a 
population average score of 60 (SD 20), where higher scores ind icate a more favorable/positive 
response with a range of 0-120. A 5- point increase in an average CLUE™ score translates into 
10% shift in the distribution of scores for population of soft contact lens wearers.22 
 
Slit-lamp findings:
Frequency and severity by eye of slit lamp findings (SLFs) including conjunctival injection, 
corneal edema, corneal neovascularization, corneal staining, ta rsal abnormalities or any other 
complications. SLFs will be evaluated at fitting and post-fitting evaluation visits including unscheduled visits.
Subject’s Reported Ocular Symptoms:
Frequency and severity by eye of subject’s reported ocular symptoms and problems with the 
study lens at fitting and post-fitt ing evaluation visits including unscheduled visits.
Lens fitting characteristics:
Frequency by eye of mechanical lens fitting characteristics including lens centration and lens
movement and overall lens fitting acceptability at fitting and 1-Week Follow-up evaluations.
Adverse events, number and reasons for discontinuation, number and reasons for unscheduled
lens replacement including lens damage will be monitored and de scriptively evaluated.
2.3. Hypotheses 
Primary HypothesesThe K-Lens will be non-inferior to the Placebo lens with respec t to monocular distance 
contact lens-corrected visual acuity. A non-inferiority margin of 0.1 logMAR (one line) units 
will be used.
3. TARGETED STUDY POPULATION 
3.1. General Characteristics  
The study populations will be healthy normal habitual contact l ens wearers that are at least 18 
years old and less than 40 years old.
3.2. Inclusion Criteria 
Potential subjects must satisfy all of the following criteria t o be enrolled in the study: 
1. The subject must read, understand, and sign the STATEMENT OF INFORMED 
CONSENT and receive a fully executed copy of the form
CR-5930, v3.0 Amendment 2.0
               Page 19 of 97JJVC CONFIDENTIAL
2. Appear able and willing to adhere to the instructions set for th in this clinical protocol
3. Between 18 and 39 (inclusive) years of age at the time of baseline  visit
4. The subject must be a habitual lens wearer for a least 6 days /week and for a minimum 
of 8 hours per day over the last month.
5.The subject’s contact lens correction must be in the range of -1.00 D to -6.00 D
(inclusive) in each eye.
6.The subject’s r efractive cylinder must be 1.00 D or less in each eye
7.Have a spherocylindrical best corrected visual acuity of 20/30 or b etter in each eye
(Snellen Visual Acuity)
3.3. Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study: 
1. Currently pregnant or lactating
2. Any systemic disease (e.g., Sjögren’s Syndrome), allergies, infectious disease (e.g., 
hepatitis, tuberculosis), contagious immunosuppressive diseases  (e.g., HIV), 
autoimmune disease (e.g. rheumatoid arthritis), or other diseas es, by self-report, which 
are known to interfere with contact lens wear and/or participat ion in the study
3. Use of systemic medications ( e.g., chronic steroid use) that are known to interfere with 
contact lens wear 
4. Any ocular allergies, infecti ons or other ocular abnormalitie s that are known to interfere 
with contact lens wear and/or participation in the study. This may include, but not be 
limited to entropion, ectropion, extrusions, chalazia, recurren t styes, glaucoma, history 
of recurrent corneal erosions, aphakia, or corneal distortion 
5. Any corneal distortion resulting from previous hard or rigid g as permeable contact lens 
wear, history of strabismus, or current monovision, multi-focal , or toric contact lens 
correction .
6. Any current use of rewetting drops or ocular medication7. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial 
keratotomy, PRK, LASIK, etc.)
8. Any Grade 3 or greater slit lamp findings (e.g., edema, corneal  neovascularization, 
corneal staining, tarsal abnormalities, conjunctival injection)  o n  t h e F D A  
Biomicroscopy Scale
9. Any previous history or signs of a contact lens-related corne al inflammatory event (e.g., 
past peripheral ulcer or round peripheral scar), or any other o cular abnormality that 
would contraindicate contact lens wear
10. Any known hypersensitivity or allergic reaction to ketotifen11. Participation in any eye drop, contact lens or lens care pro duct clinical trial within 14
days prior to study enrollment
12. Employee or immediate family member of an employee of clinical  site (e.g., 
Investigator, Coordinator, Technician)
CR-5930, v3.0 Amendment 2.0
               Page 20 of 97JJVC CONFIDENTIAL
3.4. Enrollment Strategy 
Study subjects will be recruited from the Institution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional R eview Board (IRB) approved 
materials.
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This is a randomized, double masked, bilateral, controlled, two -arm parallel group, multi-site,
1-week dispensing study. Approximately 132 subjects will be scree ned and randomly assigned 
to either K-Lens or Placebo using 2:1 ratio (i.e. 2/3 of subjects o n the K-Lens arm and 1/3 on 
the Placebo arm). The goal is for a sample size of 120 (80 subje cts in K-lens and 40 subjects 
in Placebo) after subjects who withdraw or are lost-to-follow-up.
The study begins with an Initial Visit (Visit 1). If a subject is found to meet all eligibility 
criteria (see Section 34.), they will be randomized and fit wit h either the K-Lens or Placebo
lens in both eyes based on the randomization scheme provided to the investigators;
otherwise, the subject will be deemed ineligible for this study. Successfully dispensed subjects at the initial visit will be sche duled for a follow-up visit
(Visit 2). The follow-up visit will occur approximately 6 to 9 d ays after the Initial Visit.
Unscheduled follow-up visits may occur during the study. Subjec ts will be advised to wear 
the study lenses at least 8 hours a day for a minimum of 6 days.
Both study lenses will be worn as a daily disposable modality. J &J Vision will provide the 
investigational sites with sufficient quantities of study lense s and supplies to complete the 
study.
The Investigator is responsible for ensuring that all subjects entering the study conform to 
subject selection criteria. The number of subjects targeted for  randomization and completion 
are as follows:Table 1: Target number of subjects by arm and site
K-Lens Placebo Total
Randomization 88 44 132
Completion 80 40 120
Number of sites 6 6 6
Subjects/site (Min-Max) 12-16 5-9 20-24
4.2. Study Design Rationale 
Randomized, double masked, controlled designs are the gold standa rd to perform scientifically
sound evaluations of the intervention by reducing bias associated  with the conduct and 
interpretation of a clinical trial and avoiding confounding fro m other factors. The unequal 
CR-5930, v3.0 Amendment 2.0
               Page 21 of 97JJVC CONFIDENTIAL
assignment using 2:1 K-Lens versus Placebo ratio was considered to  gain additional 
information on the K-Lens produced on the new JJVC manufacturing li ne in Limerick, Ireland.
4.3. Enrollment Target and Study Duration 
xThis study will target to enroll approximately 132 subjects (88 subjects in K-lens arm 
and 44 in Placebo arm) with a minimum of 120 subjects to complet e (80 subjects in K-
lens arm and 40 in Placebo arm) .
xSubjects will be considered enrolled in this trial only after t hey have reviewed and 
signed the informed consent.
xThe study duration will be approximately 8 weeks and there will be a total of 2 visits
5. TEST ARTICLE ALLO CATION AND MASKING 
5.1. Test Article Allocation  
Subjects will be randomly assigned to either K-Lens or Placebo arm based on a computer-
generated randomization schedule prepared before the start of th e study. The randomization 
will be stratified by investigational site and randomly permuted  blocks of 3 assignments will 
be used to achieve 2:1 K-Lens versus Placebo ratio within each study site. 
Randomization must be performed at the initial visit. The follo wing must have occurred prior 
to randomization: 
xInformed consent has been obtained 
xIt has been determined that the subject meets all the inclusion / exclusion criteria 
xSubject history and baseline information has been collected 
When the trial fitting assessment is ready to be conducted, the following steps should be 
followed:
1. Investigator or designee (documented on the Delegation Log) will consult the 
randomization scheme to obtain the study test article assignmen t for that subject prior 
to dispensing. 
2.Investigator or designee will record the subject’s number on the appropriate line of the randomization scheme. 
3. Investigator or designee will pull the appropriate test artic les from the study supply. 
All test articles that were opened, whether dispensed or not, must be recorded on the Test Article Accountability Log in the “Lenses Dispensed” section. 
5.2. Masking 
This is a double-masked study where subjects, investigators are  masked to the identity of the 
study lenses during the study period. Every attempt will be mad e to keep the other clinical trial 
personnel involved in the study (e.g. Data management, Biostati stician and Clinical 
Operations) unaware of the identity of the study lenses.  The identity of the study lenses will 
be masked by over labeling the blister packs with a label contai ning the study number, lot 
number, sphere power, expiration date and the randomization cod es. Only the personnel 
involved in the over labeling and the Statistician generating the randomization scheme will 
CR-5930, v3.0 Amendment 2.0
               Page 22 of 97JJVC CONFIDENTIAL
6.2. Ancillary Supplies/Products  
None allowed.
6.3. Administration of Test Articles 
Test articles will be dispensed to subject meeting all eligibili ty requirements, including any 
dispensing requirements set forth in this clinical protocol. Subjects will be dispensed an 
adequate supply of test articles to complete the study. Lost or damaged test articles may be 
replaced at the discretion of the Investigator and/or the Spons or.
6.4. Packaging and Labeling 
The test articles will be packaged in blisters as the primary pa ckaging. The test article will be 
over-labeled to mask the subject/Investigators to the identity of the lens. The test articles will
be in investigational cartons sealed with a tamper evident seal.
Storage Conditions
Test articles will be maintained at controlled room temperature.  Controlled room temperature 
is the temperature maintained thermostatically that encompasses  at the usual and customary 
working environment of 20° –25°C (68°–77°F).
Excursions between 15° and 30°C (59° and 86°F) are allowed and transient spikes up to 40°C 
are permitted as long as they do not exceed 24 hours.Temperatures above 30°C that exceed 24 hours and any temperatur e spikes above 40°C will 
require a non-conformance investigation.  The investigation wil l be conducted by the J&J 
Vision, R&D Quality Systems Stability Group.  As part of the inv estigation conclusions, a 
final disposition of the lots involved with the temperature excursion will be required.  Test articles should remain in their closed secondary cartons d uring storage to minimize light 
exposure.
Test articles must be kept under secure conditions.
6.5. Collection and Storage of Samples 
When possible, any lens or test article associated with an Adverse  Events and/or a Product 
Quality Complaint must be retained and stored in a glass vial w ith moderate solution pending
directions from the sponsor for potential return back to J&J Visi on.
6.6. Accountability of Test Articles 
J&J Vision Care, Inc. will provide the Investigator with sufficie nt quantities of study articles 
and supplies to complete the investigation.  The Investigator i s asked to retain all lens shipment 
documentation for the test article accountability records. 
Test article must be kept in a locked storage cabinet, accessibl e only to those assigned by the 
Investigator for dispensing. The Investigator may delegate this  activity to authorized study site 
personnel listed on the Site Delegation Log. All test articles must be accounted.  This includes:
CR-5930, v3.0 Amendment 2.0
               Page 24 of 97JJVC CONFIDENTIAL
1.16 Lens Power 
Modification (if applicable)Adjust the lens power if the subject’s best 
sphere over -refraction is not plano. 
One power modification is allowed .
If the subject’s best sphere over -refraction is 
not plano, the subject will have to return no
sooner than the following day, since subjects 
are not allowed to wear more than one lens per eye per day. When a subject returns for another lens, new baseline information must be recorded (starting with step 1.7), and then proceed per protocol through the remaining Visit 1 steps.  
1.17 Subject Reported 
Ocular SymptomsSubjects will respond to a verbal open-ended
symptoms questionnaire.
1.18 Subjective Lens Fit 
AssessmentEvaluate overall lens fit acceptance 
(acceptable or unacceptable) based on 
centration, movement and other fitting 
characteristics.
An unacceptable fit is deemed by one of the 
following criteria: 
xlimbal exposure at primary gaze or 
with extreme eye movement;
xedge lift;
xexcessive movement in primary and 
up gaze; or 
xinsufficient movement in all three of 
the following conditions: primary 
gaze, up gaze, and push up test.
Note :if lens fit is unacceptable subject will 
be discontinued from the study.
1.19 Distance ETDRS LogMAR Visual Acuity Perform monocular distance ETDRS LogMAR visual acuity test at a 4
-meter 
distance over the test eye only under the following condition:
xbright illumination (e.g., >400 lux ),
high luminance, with high contrast 
charts (HLHC); 
The P recision Vision 4- meter high contrast 
ETDRS charts (Chart 1 and Chart 2) will be used.One
measurement will be recorded per eye.
CR-5930, v3.0 Amendment 2.0
               Page 29 of 97JJVC CONFIDENTIAL
1.20 Exit Snellen VA Record subjects’ distance visual acuity, OD, 
OS and OU to the nearest letter.
1.21 Continuance For the subject to continue in the study, they 
must meet all three of the following criteria:
xVisual acuity is 20/30 or better OD 
and OS
xThe lens fit is acceptable OD and OS
xInvestigator approval.  If the 
Investigator does not approve the 
dispensing of the first study lens, then 
the study is terminated for that 
subject.
1.22 Dispense The lenses will be dispensed for a 6-9 day 
wearing period.  During this time, they will be instructed to wear the lenses at least 6 days and at least 8 hours per
day that they are 
worn.
xDispense enough lenses to last the 
subject to their scheduled follow- up
visit.  Do not dispense extras*.
xThe lenses will be worn as daily 
wear/daily disposable only.
xRewetting drops are not permitted 
xA patient instruction booklet will be 
provided.
xSubjects will be scheduled for their 1-
week follow-up visit, 
*Note: In the event a lens is lost or 
damaged, the subject will return to the clinical site for replacement.  As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then returned to the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.
 
 
CR-5930, v3.0 Amendment 2.0
               Page 30 of 97JJVC CONFIDENTIAL
7.4. Laboratory Procedures  
Not Applicable
8. SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria 
Subjects are considered to have completed the study if they:
xprovided informed consent; 
xthey are eligible;
xhave not withdrawn/discontinued from the study for any reason described in Section 
8.2
xcompleted all visits through the final visit 2
8.2. Withdrawal/Discontinuation from the Study 
A subject will be withdrawn from the study for any of the follo wing reasons:
xSubject death during the study period
xSubject withdrawal of consent
xSubject not compliant to protocol 
xSubject lost to follow-up 
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant)
xSubject develops significant or serious adverse events causing discontinuation of study 
lens wear. Greater than 2 consecutive days of missed lens wear will lead to 
discontinuation.
xSubjects who have experienced a Corneal Infiltrative Event (CIE)
xInvestigator’s clinical judgment regarding the su bject safety reasons (that it is in the 
best interest of the subject to stop treatment)
xSubject missed any study visits
xSubject not compliant with study lens wear schedule
xSubject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled)
xComplete the Final Evaluation, indicating the reason that the s ubject was discontinued 
from the study
xRecord the spherocylindrical refraction with best corrected distance visual acuity 
xCollect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in Section 7.2.
xCollect all unused test article(s) from the subject
An additional subject will not be enrolled if a subject discontinue s from the study prematurely.
CR-5930, v3.0 Amendment 2.0
               Page 34 of 97JJVC CONFIDENTIAL
In cases where a subject is lost to follow-up, every possible e ffort must be made to contact the 
subject and determine the reason for discontinuation/withdrawal . The measures taken to 
follow up must be documented including two written attempts and  a certified letter (or 
equivalent) as the final attempt. 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION 
Concomitant medications will be  documented during screening and  updated during the study.  
Disallowed medications or any concomitant therapies that are dis allowed for this study 
include: Any ocular medications or any systemic medications tha t (e.g., chronic steroid use) 
that are known to interfere with contact lens wear.
10. DEVIATIONS FROM THE PROTOCOL 
Investigator will notify study sponsor upon identification of a  protocol deviation. Major 
protocol deviations must be reported to the sponsor within 24 ho urs after discovery of the 
protocol deviation.  The Investigator will report deviations pe r IRB/IEC requirements. All 
deviations will be tracked and corrective actions implemented a s appropriate. 
If it becomes necessary for the Investigator to implement a dev iation in order to eliminate an 
immediate hazard to the trial subject, the Investigator may implement the deviation 
immediately without notification to the sponsor. Within 24 hour s after the implemented 
deviation, the Investigator must notify and provide the rational e to the Sponsor and, as
required, the IEC/IRB. 
Any protocol deviation that could impact the primary endpoints w ill result in the subject being 
excluded from the Per-Protocol analysis population.
11. STUDY TERMINATION 
The occurrence of one or more Unanticipated Serious Adverse Dev ice Effect (USADE), or 
any SAE where the relationship to study agent cannot be ruled o ut, may result in stopping 
further dispensing of test article.  In the event of a USADE or  SAE, the Sponsor may unmask 
the treatment regimen for the subject(s) and will discuss this with the Investigator before any 
further subjects are enrolled.
The Sponsor will determine when a study will be stopped.  The Pr incipal Investigator always 
has the discretion to initiate stopping the study based on pati ent safety or if information 
indicates the study’s results are compromised.
JJVC reserves the right to terminate the study at any time for a ny reason.  Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreaso nable risk is determined.  The 
study can be terminated by the Principal Investigator at the in dividual clinical site due to 
specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.   
CR-5930, v3.0 Amendment 2.0
               Page 35 of 97JJVC CONFIDENTIAL
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all a dverse events.  If it is 
determined that an adverse event presents an unreasonable risk,  the investigation, or that part 
of the investigation presenting the risk, will be terminated, a s soon as possible.
Should the study be terminated (either prematurely or as schedul ed), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS 
A Product Quality Complaint (PQC) refers to any written, electr onic, or oral communication 
that alleges deficiencies related to the identity, quality, dur ability, reliability, safety, 
effectiveness or performance of test articles after they have been released for clinical trial use.  
Potential complaints may come from a variety of sources includi ng but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints:
xSubject satisfaction inquiri es reported via “Subjective Questionnaires” and “Patient 
Reported Outcomes (PRO)”.
xClinical test articles that are stored improperly or damaged af ter receipt at the 
investigational site.
xLens replacements that occur due to drops/fall-outs.
xDamage deemed by clinicians or clinical staff to be caused by h andling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, e tc.), only in situations where 
there is no deficiency alleged by the subject.
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be recorded in the EDC system, which will trigger an automatic ema il notification to the 
appropriate COM/CRA and Clinical QA representative. In cases wh ere the EDC system in use 
is not configured to send automatic notifications or when an EDC  system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery  that a PQC has occurred.  
Upon receipt of the EDC notif ication, the COM/CRA will contact the study site to collect 
additional information which will include:
xDate the complaint was received/recorded in the EDC System (Dat e of Sponsor 
Awareness)
xWho received the complaint
xStudy number
xClinical site information (contact name, site ID, telephone num ber)
xLot number(s)
xUnique Subject Identifier(s)
xIndication of who first observed complaint (site personnel or s ubject)
xOD/OS indication, along with whether or not the lens was insert ed
xAny related AE number if applicable
xDetailed complaint description (scheduled/unscheduled visit, we ar time, symptoms, 
resolution of symptoms, etc.)
CR-5930, v3.0 Amendment 2.0
               Page 36 of 97JJVC CONFIDENTIAL
xEye Care Provider objective (slit lamp) findings if applicable
xConfirmation of product availability for return (and tracking information, if available), 
or rationale if product is not available for return (Refer to Form Control No. VCT-0152 
for test article return instructions)
Once a complaint is received, it will be assessed by the COM, C RA, or trained site personnel 
to determine if it is an Adverse Event/Serious Adverse Event (A E/SAE).  If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel wi ll follow Section 13 of this 
protocol. If the AE/SAE was potentially the result of a product  quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by the site i n error.  In this event, the 
PQC forms will be marked “Intentionally Left Bl ank” or “ILB”.  Justification for ILB must be 
documented.
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) – An AE is “any untoward medical oc currence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investigational  medical device. 
Note 1 to entry: This definition includes events related to the investi gational medical device 
or the comparator.
Note 2 to entry: This definition includes events related to the procedu res involved.
Note 3 to entry: For users or other persons, this definition is restricted to events related to 
investigational medical devices .”1
An AE includes any condition (i ncluding a pre-existing conditio n) that:
1. Was not present prior to the study, but appeared or reappeare d following initiation of 
the study 
2. Was present prior to the study, but worsened during the study . This would include any 
condition resulting from concomitant illnesses, reactions to co ncomitant medications, 
or progression of disease states 
3. Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor imm ediately upon learning of the eve nt
Serious Adverse Event (SAE) –An SAE is any untoward medical occurrence that:
xResults in death
xIs life threatening
xRequires in-patient hospitalization or prolongation of existing  hospitalization
xResults in persistent or signif icant disability/incapacity (e.g ., a sight threatening event, 
a significant persistent or permanent change, impairment, damag e, or disruption to the 
subject’s body)
xIs a congenital anomaly/birth defect, or
CR-5930, v3.0 Amendment 2.0
               Page 37 of 97JJVC CONFIDENTIAL
xRequires intervention to prevent permanent damage (the use of t he test article resulting 
in a condition which requires medical or surgical intervention to preclude permanent 
impairment of the body structure or a body function).  Importan t medical events that 
may not result in death, be life-threatening, or require hospit alization may be 
considered an SAE when, based upon appropriate medical judgment , they may 
jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the above definition
Diagnoses and conditions that are considered Ocular Serious Adv erse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best spectacle corrected visual acuity eq uivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events –Those events that are usually symptomatic and warrant 
discontinuation (temporary or permanent) of the test article (e xcluding Serious Adverse 
Events).  
Diagnoses and conditions that are considered Ocular Significant  Adverse Events include, but 
not limited to the following:
xContact Lens Induced Peripheral Ulcer (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Arcuate Lesions (SEALs)
xAny Temporary Loss of >2 Lines of BSCVA
xOther grade 3 or higher corneal findings, such as abrasions or edema
xNon-contact lens related corneal events - e.g. Epidemic Keratoco njunctivitis (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation >2 weeks
Non-Significant Adverse Events –Those conditions that are usually asymptomatic and 
usually do not warrant discontinuation (temporary or permanent)  of the test article.  However, 
the Investigator may choose to treat as a precautionary measure .
Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, 
but not limited to the following:
CR-5930, v3.0 Amendment 2.0
               Page 38 of 97JJVC CONFIDENTIAL
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or signific ant adverse event, which 
necessitates temporary lens discontinuation <2 weeks
Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.
Note 1 to entry: This definition includes adverse events resulting from  insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device.
Note 2 to entry: This definition includes any event resulting from use error or from 
intentional misuse of the investigational medical device.”1
Unanticipated Adverse Device Effect (UADE) –Any serious adverse effect on health or 
safety or any life-threatening problem or death caused by, or a ssociated with, the test article, 
if that effect, problem, or death was not previously identified  in nature, severity, or degree of 
incidence in the investigational plan, Investigator’s Brochure or protocol, or any other 
unanticipated serious problem associated with the test article that relates to the rights, safety 
and welfare of subjects.
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure 
the events are categorized c orrectly.  Elements of categorizati on will include:
xSeriousness/Classifications (see definition in Section 13.1)
xCausality or Relatedness –i.e. the relationship between the test article, study treatment 
or study procedures and the adverse event (not related; unlikel y related; possibly 
related; related - see definition in Section 13.2.1)
xAdverse Event Severity –Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild; moderate; severe for all events - see definition in 
Section 13.2.2)
xOutcome –not recovered or not resolved; recovering or resolving; recover ed or 
resolved with sequelae; recovered or resolved; death related to adverse event; unknown
xActions Taken –none; temporarily discontinued; permanently discontinued; other
13.2.1 Causality Assessment 
Causality Assessment –A determination of the relationship between an adverse event an d the 
test article, study treatment, or study procedure. The test art icle, study treatment or study 
procedure relationship for each adverse event shall be determin ed by the Investigator using 
these explanations:
CR-5930, v3.0 Amendment 2.0
               Page 39 of 97JJVC CONFIDENTIAL
xNot Related- An adverse event that is not related to the use of the test article, study 
treatment or study procedures.
xUnlikely Related –An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely.
xPossibly Related –An adverse event that might be due to the use of the test artic le, or 
to the study treatment or study procedures. An alternative expl anation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive.  The relati onship in time is 
reasonable.  Therefore, the causal relationship cannot be exclu ded.
xRelated –An adverse event that is listed as a possible adverse effect (d evice) or adverse 
reaction (drug) and cannot be reasonably explained by an alternative explanation, e.g. 
concomitant treatment of concomitant disease(s).  The relations hip in time is very 
suggestive, e.g. it is confirmed by de-challenge and re-challen ge. 
13.2.2 Severity Assessment 
Severity Assessment –A qualitative assessment of the degree of intensity of an adverse event 
as determined by the Investigator or reported to him/her by the  subject.  The assessment of 
severity is made irrespective of test article, study treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to t he following scale:
xMild –Event is noticeable to the subject, but is easily tolerated and  does not interfere 
with the subject’s dai ly activities
xModerate –Event is bothersome, possible requiring additional therapy, and  m a y  
interfere with the subject’s daily activities
xSevere –Event is intolerable, necessitates additional therapy or altera tion of therapy 
and interferes with the subje ct’s daily activities
13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse events (ocular and non -ocular) begins when the 
subjects are exposed to the test article, study treatment or st udy procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the condition deterior ates at any time during the study 
it will be recorded and reported as an AE. Untoward medical eve nts rep orted after the subject’s 
exit from the study will be recorded as adverse events at the d iscretion of the Investigator.
Upon finding an adverse event, the Principal Investigator will document the condition in the subject record and in the eCRFs. He/she will complete the Adver se Event /eCRF.  
Complete descriptions of all adverse events must be available i n the subject record. All 
Adverse Events including local and systemic reactions not meeting the criteria for “serious 
adverse events” shall be captured o n the appropriate case report form or electronic data system. 
All adverse events occurring while the subject is enrolled in t he study must be documented 
appropriately regardless of relationship.  
CR-5930, v3.0 Amendment 2.0
               Page 40 of 97JJVC CONFIDENTIAL
It is the Investigator’s responsibility to maintain documentation of each reported adverse event. 
All adverse events will be followed in accordance with applicab le licensing requirements.  
Such documentation will include the following:
xAdverse event (diagnosis not symptom)
xDrawings or photographs (where appropriate) that detail the fin ding (e.g., size, 
location, and depth, etc.) 
xDate the clinical site was notified 
xDate and time of onset
xDate and time of resolution
xAdverse event classification, severity, and relationship to tes t articles, as applicable
xTreatment regimen instituted, including concomitant medications  prescribed, in 
accordance with applicable licensing requirements
xAny referral to another health care provider if needed
xOutcome, ocular damage (if any)
xLikely etiology
xBest corrected visual acuity at the discovery of the event and u pon conclusion of the 
event
In addition, if an infiltrate(s) is present, he/she will comple te the Corneal Infiltrate Assessment 
eCRF.  Where necessary, a culture of the corneal lesion will be  collected to determine if the 
infection is microbial in nature .  If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be documented to allow a n assessment of the duration 
of the event at each level of intensity to be performed.  Adver se events characterized as 
intermittent require documentation of the onset and duration of  each episode. Changes in the 
assessment of relationship to the Test Article shall also be cl early documented.
Subjects who present with an adverse event shall be followed by  the Investigator, within 
licensure, until all signs and symptoms have returned to pre-tr eatment status, stabilized, or 
been satisfactorily resolved.  If further treatment beyond lice nsure is required, the patient will 
be referred to the appropriate health care provider.  The Inves tigator will use his/her clinical 
judgment as to whether or not a subject reporting with an adverse event will continue in the 
study.  If a subject is discontinued from the study, it will be the responsibility of the Investigator 
to record the reason for discont inuation.  The Investigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects  with ongoing adverse 
events related to the test articl e, study treatment or study pro cedures, as of the final study visit 
date, should be followed to resolution of the adverse event or until referral to an appropriate 
health care provider, as recommended by the Investigator. Non-o cular adverse events that are 
not related to the test article, study treatment, or study proc edures may be recorded as 
“ongoing” without further follow -up.
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by  e-mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
CR-5930, v3.0 Amendment 2.0
               Page 41 of 97JJVC CONFIDENTIAL
adverse events, and 2 days from  discovery for any non-significa nt adverse event.  In addition, 
a written report will be submitted by the Principal Investigato r to the IEC/IRB according to 
their requirements (Section 13.4.2).  The report will comment w hether or not the adverse event 
was considered to be related to the test article, study treatme nt or study procedures.
13.4.1 Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring during the study period as soon as possible by e-mail, fax, or telephone, but no later than 
24 hours following discovery of the event.  The Investigator is obligated to pursue and obtain information requested by the Sponsor in addition to that information reported on the eCRF. All subjects experiencing a serious/significant adverse event must b e followed up and all outcomes 
must be reported.
When medically necessary, the Investigator may break the random ization code to determine 
the identity of the treatment that the subject received.  The S ponsor and study monitor should 
be notified prior to unmasking the test articles.In the event of a serious/significant adverse event, the Investi gator must:
xNotify the Sponsor immediately
xObtain an d maintain in the subject’s records all pertinent medical information and 
medical judgment for colleagues who assisted in the treatment a nd follow-up of the 
subject
xProvide the Sponsor with a complete case history which includes  a statement as to 
whether the event was or was not related to the use of the test  article
xNotify the IEC/IRB as required by the IEC/IRB reporting procedure  according to 
national regulations
Unanticipated (Serious) Adverse Device Effect (UADE)
In the event of an Unanticipated (Serious) Adverse Device Effec t (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as s oon as possible, but no later 
than 24 hours after the Investigator first learns of the effect .  This report is in addition to the 
immediate notification mentioned above.
The Sponsor must conduct an evaluation of the UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participating Investigators wi thin 10 working days after 
the Sponsor first receives notification of the effect.
Non-Serious Adverse Events
All non-serious adverse events, including non-serious adverse d evice effects, will be reported 
to the sponsor by the Investigator no later than 2 days from di scovery.
13.4.2 Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB ’s written guidelines. Each clinical site will refer to and follow any guidelines set forth  
CR-5930, v3.0 Amendment 2.0
               Page 42 of 97JJVC CONFIDENTIAL
by their Approving IEC/IRB. Each clinical site will refer to and  follow any guidelines set forth 
by their local governing Health Authorities.
The Sponsor will report applicable Adverse Events to the local health authorities according the 
written guidelines, including reporting timelines.
13.4.3 Event of Special Interest 
None
13.5. Reporting of Pregnancy 
Subjects reporting pregnancy (by self-report) during the course  of the study will be 
discontinued after the event is recorded as an Adverse Event.  Once discontinued, pregnant 
participants and their fetuses will not be monitored for study related purposes.  At the 
Investigator ’s discretion, the study participant may be followed by the Inve stigator through 
delivery. However, this data will not be collected as part of t he clinical study database.  
Pregnant participants are not discontinued from contact lens or  solution related studies for 
safety concerns, but due to general concerns relating to pregna ncy and contact lens use.  
Specifically, pregnant women are discontinued due to fluctuatio ns in refractive error and/or 
visual acuity that occur secondary to systemic hormonal changes , and not due to unforeseen 
health risks to the mother or fetus.
14. STATISTICAL METHODS 
14.1. General Considerations 
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A 
general description of the statistical methods to be implemente d in this clinical trial is outlined 
below. For more details, refer to the stand-alone Statistical An alysis Plan (SAP).
All data summaries and statistical analyses will be performed using the SAS software version 
9.4 or higher (SAS Institute, Cary, NC). Throughout the analysi s of data, the results for each 
subject/eye will be used when available for summarization and s tatistical analysis.
Summary tables (descriptive statistics and/or frequency tables)  will be provided for all baseline 
variables, efficacy variables and safety variables as appropriate.  Continuous variables will besummarized with descriptive statistics (n, mean, standard devia tion (SD), median, minimum 
and maximum). Frequency count and percentage of subjects or eye s within each category will 
be provided for categorical data.
14.2. Sample Size Justification 
The study is designed to evaluate the clinical performance of K -Lens produced on the new 
JJVC manufacturing line in Limerick, Ireland with the primary ob jective to show that the K-
Lens is non-inferior to the Placebo lens with respect to best-corr ected distance visual acuity.
The plan is to enroll 132 eligible subjects with a target comple tion of 120 subjects (80 subjects 
in K-Lens and 40 subjects in Placebo). 
CR-5930, v3.0 Amendment 2.0
               Page 43 of 97JJVC CONFIDENTIAL
The sample size of 120 subjects is considered sufficiently large t o test for non-inferiority with 
a minimum statistical power of 85% and two-sided type I error of 0.05. Assuming a perfect 
correlation between left eye visual acuity and the right eye visual acuity (worst case scenario),
the total sample size (n) required to achieve 85% power with two- sided type I error of 0.05 
was calculated for different scenarios of mean difference ( ο= K-Lens –Placebo) and common 
standard deviation ( ߪ  )in the two arms. The results are summarized in the Table belo w:
CR-5930, v3.0 Amendment 2.0
               Page 44 of 97JJVC CONFIDENTIAL
Table 4: Sample size for different scenarios of mean  οandߪ
ο ߪ n
0 0.05 15
0 0.01 45
0.04 0.05 33
0.04 0.1 117
The sample size calculation was conducted using the PROC POWER Procedure (SAS/STAT 
14.1, SAS Institute, 2015) for two-sample means with allocation  weight of 2:1. 
Justification of Non-inferiority margin:
The non-inferiority margin of one line loss on best-corrected d istance visual acuity was
considered based on the work done by Jane E. Lovie-Kitchin and B rian Brown on evaluating 
the repeatability and intercorrelations of five standard vision tests in subjects with normal 
vision.  The authors concluded that one line change is, on average, a useful criterion to adopt 
on clinical decision making23.
14.3. Analysis Populations 
Per-Protocol Population: 
All subjects who have successfu lly completed all visits and did  not substantially deviate from 
the protocol as determined by the trial cohort review committee  prior to database hard lock. 
Justification of excluding subjects with protocol deviations in the per-protocol population set 
will be documented in a memo to file.
Safety Population:
All subjects who were administered any test article excluding s ubjects who drop out prior to 
administering any test article . At least one observation should be recorded.
The primary analyses will be performed on per-protocol populati on. Additional sensitivity
analyses may be conducted on the safety population.
14.4. Level of Statistical Significance 
All planned analysis will be conducted with an overall type I er ror rate of 5%. Unless otherwise 
specified, all statistical tests will be 2-sided.
14.5. Primary Analysis  
Contact lens monocular distance best-corrected visual acuity on  logMAR scale will be 
analyzed using a linear mixed effects model to test for non-infe riority of K-Lens relative to 
Placebo. Lens group will be included as fixed effects in the model; and investigator site as 
random effect. The covariance matrix between the left eye visual  acuity and right eye visual 
acuity will be selected based on the finite-sample Corrected Akaike’s Information Criterion.24
Covariance structures considere d include Compound Symmetry (CS) and Unstructured (UN).
The covariance structure that returns the lowest AICC will be s elected as the structure that best 
fit the data. Heterogeneous covariance structures across study lens groups will be considered 
CR-5930, v3.0 Amendment 2.0
               Page 45 of 97JJVC CONFIDENTIAL
when appropriate. The log-likelihood ratio test will be used to  test for the homogeneity between 
the residual covariance structures. The Kenward and Roger metho d will be used to calculate 
the denominator degree of freedom.25
The null and alternative hypotheses for non-inferiority of K-Le ns relative to Placebo are as 
follows:
ܪ଴ǣο൒ͲǤͳ
ܪ஺ǣο൏ͲǤͳ ,
whereοis the mean difference in visual acuity between K-Lens and Placebo (K-Lens minus 
Placebo). The non-inferiority test will be based on the least-sq uare mean difference (K-Lens
minus Placebo) and corresponding 95% confidence interval calculated using the final selected 
model. The upper bound of the 95% confidence interval will be co mpared to the non-inferiority 
margin of 0.1 LogMAR. If the upper bound is less than 0.1, K-Len s will be considered non-
inferior to Placebo with respect to visual Acuity.
14.6. Secondary Analysis 
Secondary endpoints will be summarized descriptively using all available data including data 
from unscheduled visits. 
14.7. Other Exploratory Analyses  
No exploratory analysis is planned for this study. Further analysis may be conducted at the 
discretion of the study responsible clinician at the end of the  study.
14.8. Interim Analysis 
There will not be an interim analysis performed for this study.  
14.9. Procedure for Handling Missing Data and Drop-Outs 
Missing or spurious values will not be imputed as the number of missing values is expected to 
be low. The count of missing values will be included in the sum mary tables and listings. 
Subject dropout is expected to be  one of the main reasons of mi ssing data in this clinical trial. 
Past clinical trials don’t provide the evidence that subject dropou t is systematic or not-at-
random. To evaluate the impact of missing data, a sensitivity an alysis will be conducted using 
multiple imputation methods if the proportion of subject dropout is greater than 15%.
14.10. Procedure for Reporting Deviations from Statistical Plan 
The analysis will be conducted according to that specified in a bove sections.  There are no 
known reasons for which it is planned to deviate from these ana lysis methods.  If for any reason 
a change is made, the change will be documented in the study re port along with a justification 
for the change.
CR-5930, v3.0 Amendment 2.0
               Page 46 of 97JJVC CONFIDENTIAL
15. DATA HANDLING AND RE CORD KEEPING/ARCHIVING 
15.1. Electronic Case Report Form/Data Collection 
The data for this study will be captured on electronic case rep ort forms (eCRFs) using the 
Bioclinica system. An authorized data originator will enter study data into the eCRFs using the 
Bioclinica system. Data collected on equipment that is not capt ured in Bioclinica will be 
formatted to the specification of t he JJVC database manager and sent to JJVC for analysis. 
External Date Sources for this study include: Not Applicable
The clinical data will be recorded on dedicated eCRFs specifica lly designed to match the study 
procedures for each visit.  Once completed, the eCRFs will be r eviewed for accuracy and 
completeness and signed by the Investigator.  The sponsor or sp onsor ’s representatives will be 
authorized to gain access to the subject recordation for the pu rposes of monitoring and auditing 
the study. Edit checks, electronic queries, and audit trails are built int o the system to ensure accurate and 
complete data collection. Data will be transmitted from the cli nical site to a secure central 
database as forms are completed  or updated, ensuring informatio n accuracy, security, and 
confidentiality. After the final database lock, the Investigato r will be provided with Individual 
Patient Profiles (IPP) including the full audit trail on electr onic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a  certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO14155:2011.
15.2. Subject Record 
At a minimum, subject record should be available for the followi ng:
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy parameters as required by the pr otocol
xa record of all adverse events
xfollow-up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable.  The first point of entry is consid ered to be the source record.
CR-5930, v3.0 Amendment 2.0
               Page 47 of 97JJVC CONFIDENTIAL
Adverse event notes must be reviewed and initialed by the Investi gator.
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial-related monitorin g, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source d ata/documents.  Should the 
clinical site be contacted for an audit by an IEC/IRB or regulato ry authority, JJVC must be 
contacted and notified in writing within 24 hours.
16.2. Confidentiality of Information 
Information concerning the investigational product and patent application processes, scientific 
data or other pertinent information is confidential and remains the property of JJVC. The Investigator may use this information for the purposes of the s tudy only. It is understood by 
the Investigator that JJVC will use information developed in thi s clinical study in connection 
with the development of the investigational product and therefo re may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an 
obligation to provide complete test results and all data develo ped during this study to the 
Sponsor.
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of da ta, include the selection of 
qualified investigators and appropriate clinical sites and revi ew of protocol procedures with 
the Principal Investigator.  The P rincipal Investigator, in turn,  must ensure that all Sub-
Investigators and clinical site pe rsonnel are familiar with the p rotocol and all study-specific 
procedures and have appropriate knowledge of the study article.
Training on case report form completion will be provided to clini cal site personnel before the 
start of the study.  The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring vis its, and after transmission to 
data management.  Any data discrepancies will be resolved with the Investigator or designee, as appropriate.
Quality Assurance representatives from JJVC may visit clinical s ites to review data produced 
during the study and to access compliance with applicable regul ations pertaining to the conduct 
of clinical trials.  The clinical sites will provide direct acc ess to study-related source 
data/documents and reports for the purpose of monitoring and au diting by JJVC and for 
inspection by local and regulatory authorities.
17. MONITORING 
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator’s designated clinical site personnel.  The monitor’s responsibilities will include:
CR-5930, v3.0 Amendment 2.0
               Page 48 of 97JJVC CONFIDENTIAL
xEnsuring that the investigation is being conducted according to  the protocol, any 
subsequent amendments, and regulatory requirements are maintain ed
xEnsuring the rights and wellbeing of subjects are protected
xEnsuring adequate resources, including facilities, laboratories , equipment, and 
qualified clinical site personnel
xEnsuring that protocol deviations are documented with correctiv e action plans, as 
applicable
xEnsuring that the clinical site has sufficient test article and supplies
xClarifying questions regarding the study
xResolving study issues or problems that may arise
xReviewing of study records and sour ce documentation verification in accordance with 
the monitoring plan
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requ irements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue 
participation.  Subjects will be told that their consent to part icipate in the study is voluntary 
and may be withdrawn at any time with no reason given and witho ut penalty or loss of benefits 
to which they would otherwise be entitled.  Only subjects who ar e fully able to understand the 
risks, benefits, and potential adverse events of the study, and provide their consent voluntarily 
will be enrolled.
18.2. Investigator Responsibility 
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance with the signed agreement, the investigational plan,  Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP), and applicable regu latory requirements.  GCP is 
an international ethical and scientific quality  standard for designing, conducting, recording, 
and reporting studies that involve the particip ation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well-being of study subjects are 
protected, consistent with the princip les of the Declaration of Helsinki 64th WMA General 
Assembly 2013 and that the clinical study data ar e credible.  The Investigator must maintain 
clinical study files in accordan ce with Section 8 of the ICH E6 guidelines on Good Clinical 
Practice (GCP), and applicable regulatory requirements.
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB) 
Before the start of the study, the Investigator (or Sponsor whe n applicable) will provide the 
IEC/IRB with current and complete copies of the following documents (where applicable):
xFinal protocol and, if applicable, amendments
xSponsor-approved informed consent form (and any other written m aterials to be 
provided to the subjects)
xInvestigator ’s Brochure (or equivalent information) and amendments
xSponsor-approved subject recruitment materials
CR-5930, v3.0 Amendment 2.0
               Page 49 of 97JJVC CONFIDENTIAL
xInformation on compensation for study-related injuries or payme nt to subjects for 
participation in the study
xInvestigator’s curriculum vitae , clinical licenses, or equivalent information (unless not 
required, as documented by IEC/IRB)
xInformation regarding funding, name of the Sponsor, institution al affiliations, other 
potential conflicts of interest , and incentives for subjects
xAny other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after IEC/IRB has given full  approval of the final protocol, 
amendments (if any), the informed consent form, applicable recr uiting materials, and subject 
compensation programs, and the Sponsor has received a copy of th is approval. This approval 
letter must be dated and must clearly identify the documents be ing approved.
During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where a ppropriate:
xProtocol amendments
xRevision(s) to informed consent form and any other written mate rials to be provided to 
subjects
xIf applicable, new or revised subject recruitment materials approved by the Sponsor
xRevisions to compensation for study-related injuries or payment  to subjects for 
participation in the study
xInvestigator’s Brochure amendments or new edition(s)
xSummaries of the status of the study (at least annually or at i ntervals stipulated in 
guidelines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and associated with the test
articles , according to the IRB’s requirements
xNew information that may adversely affect the safety of the sub jects or the conduct of 
the study
xMajor protocol deviations as required by the IEC/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is responsible for the study  at the clinical site
xAny other requirements of the IEC/IRB
For protocol amendments that increase subject risk, the amendme nt and applicable informed 
consent form revisions must be submitted promptly to the IEC/IR B for review and approval 
before implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where req uired) will notify the IEC/IRB 
about the study completion.  Documentation of this notification  must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
CR-5930, v3.0 Amendment 2.0
               Page 50 of 97JJVC CONFIDENTIAL
18.4. Informed Consent 
Each subject must give written consent according to local requi rements after the nature of the 
study has been fully explained. The consent form must be signed before performance of any 
study-related activity. The consent form that is used must be a pproved by both the Sponsor 
and by the reviewing IEC/IRB. The informed consent is in accord ance with principles that 
originated in the Declaration of Helsinki,3current ICH2and ISO 141551guidelines, applicable
regulatory requirements, and Sponsor Policy.
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort it may e ntail. Subjects will be informed 
that their participation is voluntary and that they may withdra w consent to participate at any 
time. The subject will be given sufficient time to read the informed consent form and the opportunity 
to ask questions. After this explanation and before entry into the study, consent should be 
appropriately recorded by means of the subject's dated signature. After having obtained the consent, a copy of the informed consent form must be given to t he subject.
If involving vulnerable population, provide description of spec ific informed consent process. 
Below is an example for study involving children as subjects:
Each subject for this study will complete an assent and a paren t or legal guardian must give 
written informed consent according to local requirements after the nature of the study has been 
fully explained. The assent and consent forms must be signed be fore performance of any study-
related activity. The assent and consent forms that are used mu st be approved by both the 
Sponsor and by the reviewing IEC/IRB. The assent and informed c onsent forms should be in 
accordance with principles that originated in the Declaration o f Helsinki,
3current ICH2and
GCP guidelines, applicable regulatory requirements, and Sponsor  policy.  Before entry into the 
study or pre-screening, the Investigator or an authorized member of the clinical site personnel 
must explain to the potential subject and parent and/or legal guardian the aims, methods, 
reasonably anticipated benefits, and potential hazards of the study or pre-screening, and any 
discomfort it may entail . Subjects and parent and/or legal gua rdian will be informed that their 
participation is voluntary and that they may withdr aw consent to participate at any time. They 
will be informed that choosing not to participate will  not affect the care the subject will receive.  
Finally, they will be told that the Investigator will maintain a subject identification re gister for 
the purposes of long-term follow-up if needed and that their records may be accessed by health 
authorities and authorized Sponsor personnel without violating the confidentiality of the 
subject, to the extent permitted by the appl icable law(s) or regulations. By signing the assent 
and informed consent form, the subject is author izing such access and agrees to be contacted 
after study completion by health authorities and authorized Sponsor personnel for the purpose 
of obtaining consent for additional safety evaluations if needed.
CR-5930, v3.0 Amendment 2.0
               Page 51 of 97JJVC CONFIDENTIAL
18.5. Privacy of Personal Data 
The collection, processing and disclosure of personal data and medical information related to 
the Study Subject, and personal data related to Principal Inves tigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curricu lum vitae) is subject to 
compliance with the Health Information Portability and Accounta bility Act (HIPAA) in the 
United States26and other applicable personal data protection and security laws and 
regulations27.  Appropriate measures will be employed to safeguard these dat a, to maintain the 
confidentiality of the person’s related health and medical information, to properly inform the 
concerned persons about the collection and processing of their personal data, to grant them 
reasonable access to their personal data and to prevent access by unauthorized persons.
All information obtained during the course of the investigation  will be regarded as confidential. 
All personal data gathered in this trial will be treated in str ictest confidence by Investigators, 
monitors, Sponsor’s personnel and IEC/IRB.  No data will be disclosed to any third party 
without the express permission of the subject concerned, with t he exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizati ons in the context of their 
investigation related activities that, as part of the investiga tion will have access to the CRFs 
and subject records.
The collection and processing of personal data from subjects en rolled in this study will be 
limited to those data that are necessary to investigate the eff icacy, safety, quality, and utility of 
the investigational pr oduct(s) used in this study.
These data must be collected and processed with adequate precau tions to ensure confidentiality 
and compliance with applicable data privacy protection laws and  regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully
xcollected for specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with these purposes
xadequate, relevant, and not excessive in relation to said purpo ses
xaccurate and, where necessary, kept current
Explicit consent for the processing of personal data will be ob tained from the participating 
subject before collection of data. Such consent should also add ress the transfer of the data to 
other entities and to other countries.The subject has the right to request through the Investigator a ccess to his personal data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taking into consi deration the nature of the request, 
the conditions of the study, and the applicable laws and regula tions.
Appropriate technical and organizational measures to protect th e personal data against 
unauthorized disclosures or access, accidental or unlawful dest ruction, or accidental loss or 
alteration must be put in place. Sponsor personnel whose respon sibilities require access to 
personal data agree to keep the identity of study subjects conf idential.
CR-5930, v3.0 Amendment 2.0
               Page 52 of 97JJVC CONFIDENTIAL
19. STUDY RECORD RETENTION 
In compliance with the ICH/GCP guidelines,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data collected from each subject, as well as all 
study documents as specified in ICH/GCP2and all study documents as specified by the 
applicable regulatory requirement(s). The Investigator/Institut ion will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at least two (2) year s after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical development of the investiga tional product. These 
documents will be retained for a longer period if required by t he applicable regulatory 
requirements or instructed by the Sponsor. It is the responsibi lity of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer n eed to be retained.
If the responsible Investigator retires, relocates, or for othe r reasons withdraws from the 
responsibility of keeping the study records, custody must be tr ansferred to a person who will 
accept the responsibility. The Sponsor must be notified in writ ing of the name and address of 
the new custodian.  Under no circumstance shall the Inves tigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.If it becomes necessary for the Sponsor or the appropriate regu latory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.
If the Investigator has a question regarding retention of study records, he/she should contact 
JJVC.
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement.  The Research Agreement will be signed by the Princi pal Investigator and a JJVC
management representative prior to study initiation.
JJVC reserves the right to withhol d remuneration for costs associated with protocol violations
such as:
xContinuing an ineligible subject in the study
xScheduling a study visit outside the subject’s acceptable visit range
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution
xCase Report Form signature
xCompletion of any follow-up action items
CR-5930, v3.0 Amendment 2.0
               Page 53 of 97JJVC CONFIDENTIAL
21. PUBLICATION 
This study will be registered on ClinicalTrials.gov by the Sponsor.
CR-5930, v3.0 Amendment 2.0
               Page 54 of 97JJVC CONFIDENTIAL
 
22. Wirth, R.J., et al., Development of the Contact Lens User Experience: CLUE Scales. 
Optom Vis Sci, 2016. 93(8): p. 801-8.
23. Lovie-Kitchin, J.E. and B. Brown, Repeatability and intercor relations of standard 
vision tests as a function of age. Optom Vis Sci, 2000. 77(8): p. 412-20.
24. Keselman, H., et al., A comparison of two approaches for selecting covariance 
structures in the analysis of repeated measurement. Communicati ons in Statistics, 
1998. Simulation & Computation(27): p. 591-604.
25. Kenward, M.G. and J.H. Roger, Small Sample Inference for Fixed Effects from 
Restricted Maximum Likelihood. Biometrics 1997. 53(3): p. 983-9 97.
26. Health Information Portability and Accountability Act (HIPAA ). 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html 
27. Data Protection Act. http://www.legislation.gov.uk/ukpga/1998/29/contents  
CR-5930, v3.0 Amendment 2.0
               Page 56 of 97JJVC CONFIDENTIAL
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) 
 
 
CR-5930, v3.0 Amendment 2.0
               Page 57 of 97JJVC CONFIDENTIAL
PRO SPECIFICATION Version 1 Final  2017-07-17Protocol 5930                 Johnson & Johnson Vision Care, Inc.                  Confidential 1
CR-5930, v3.0 Amendment 2.0  
               Pa ge 58 of 97JJVC CONFIDENTIAL
PRO SPECIFICATION Version 1 Final  2017-07-17Protocol 5930                 Johnson & Johnson Vision Care, Inc.                  Confidential 2
CR-5930, v3.0 Amendment 2.0  
               Pa ge 59 of 97JJVC CONFIDENTIAL
PRO SPECIFICATION Version 1 Final  2017-07-17Protocol 5930                 Johnson & Johnson Vision Care, Inc.                  Confidential 3
CR-5930, v3.0 Amendment 2.0  
               Pa ge 60 of 97JJVC CONFIDENTIAL
APPENDIX B: PATIENT INSTRUCTION GUIDE   
Patient Instruction Guide will be provided separately. 
CR-5930, v3.0 Amendment 2.0
               Page 61 of 97JJVC CONFIDENTIAL
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) 
1·DAY ACUVUE®
CR-5930, v3.0 Amendment 2.0
               Page 62 of 97JJVC CONFIDENTIAL
APPENDIX D: CLINICAL  TECHNICAL PROCEDURE S   
 Lens Fitting Characteristics
 Subject Reported Ocular Symptoms/Problems
 Determination of Distance Spherocylindrical Refractions
 Biomicroscopy Scale
 Distance and Near Visual Acuity Evaluation
 Distance logMAR Visual Acuity Measurement Procedure
CR-5930, v3.0 Amendment 2.0
               Page 65 of 97JJVC CONFIDENTIAL
 LENS FITTING CHARACTERISTICS  
CR-5930, v3.0 Amendment 2.0
               Page 66 of 97JJVC CONFIDENTIAL
PPage 4 of 6 
  
 
 
 
 
  
 
 
 
 
CR-5930, v3.0 Amendment 2.0  
               Pa ge 70 of 97JJVC CONFIDENTIAL
PPage 5 of 6 
 CR-5930, v3.0 Amendment 2.0  
               Pa ge 71 of 97JJVC CONFIDENTIAL
PPage 6 of 6 
  
 
 
  
 
 
CR-5930, v3.0 Amendment 2.0  
               Pa ge 72 of 97JJVC CONFIDENTIAL
VCT-0007 (6) SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS  
 
 
 
CR-5930, v3.0 Amendment 2.0  
               Pa ge 73 of 97JJVC CONFIDENTIAL
 DETERMINAT ION OF DISTANCE SPHE ROCYLINDRICAL 
REFRACTIONS  
CR-5930, v3.0 Amendment 2.0
               Page 75 of 97JJVC CONFIDENTIAL
 BIOMICROSC OPY SCALE  
CR-5930, v3.0 Amendment 2.0
               Page 82 of 97JJVC CONFIDENTIAL
 DISTANCE A ND NEAR VISUAL ACUIT Y EVALUATION  
CR-5930, v3.0 Amendment 2.0
               Page 88 of 97JJVC CONFIDENTIAL
 DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT 
PROCEDURE  
CR-5930, v3.0 Amendment 2.0
               Page 93 of 97JJVC CONFIDENTIAL
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE 
Protocol Number and Title: CR-5930 Clinical Evaluation of etafil con A with Ketotifen
Version and Date: v3.0, Amendment 2.0 31 October 2017
I have read and understand the protocol specified above and agree on its content.  
I agree to conduct this study according to ISO 14155,1GCP and ICH guidelines,2the 
Declaration of Helsinki,3United States (US) Code of Federal Regulations (CFR),4and the 
pertinent individual country laws/regulations and to comply wit h its obligations, subject to 
ethical and safety considerations. The Principal Investigator is responsible for ensuring that all 
clinical site personnel, including Sub-Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical trials during and after study com pletion.
I will assure that no deviation from, or changes to the protocol will take place without prior agreement from the Sponsor and documented approval from the Ins titutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard( s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere 
to all ICH
2regulations and GCP guidelines regarding clinical trials during  and after study 
completion.
All clinical site personnel involved in the conduct of this stu dy have completed Human 
Subjects Protection Training. 
I agree to ensure that all clinical site personnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitmen ts.
I shall not disclose the information contained in this protocol  or any results obtained from this 
study without written authorization.
Principal 
Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-5930, v3.0 Amendment 2.0
               Page 97 of 97JJVC CONFIDENTIAL
Electronic Signature Report
file:///C|/Siemens/tc11/rac/temp/1509719668700-tv_crf_rpt_34464 _0_03112017_1034 html[11/3/2017 10:34:58 AM]Electronic Signature Report
Job Name: VIS-CR-005930/A-R&D Clinical Study
Revision: VIS-CSPR-005767/3-Clinical Protocol
Title: VIS Clinical Study Protocol Approval
Status: Approved
System: Vision Care R&D Knowledge Management
Generated By:  Cook, Kara
Generated On: 2017-11-03 10:34:26
Signoff Details
Function/Role Approval Details 
Biostatistician
ApprovalParticipant WWID Decision Decision Date
Toubouti, Moulay Youssef 373334 Approved 2017-11-03T09:38:08
Function/Role Approval Details 
Clinician
ApprovalParticipant WWID Decision Decision Date
Pall, Brian 176727 Approved 2017-11-01T21:52:13
Function/Role Approval Details 
Clinical Research
Manager
ApprovalParticipant WWID Decision Decision Date
Anderson, Annette 6558 Approved 2017-11-01T16:26:50
Function/Role Approval Details 
Other ApprovalParticipant WWID Decision Decision Date
Paulk, Randall 375676 Approved 2017-11-03T09:47:57
Moody, Kurt 358947 Approved 2017-11-01T15:52:46
Dalton, Joseph 372536 Approved 2017-11-01T16:15:48